At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PRME Prime Medicine, Inc.
Pre-Market Trading 09-20 08:20:31 EDT
3.91
-0.07
-1.76%
盘前3.91
+0.000.00%
08:02 EDT
High4.19
Low3.89
Vol736.72K
Open4.16
D1 Closing3.98
Amplitude7.66%
Mkt Cap454.74M
Tradable Cap211.83M
Total Shares116.30M
T/O2.93M
T/O Rate1.36%
Tradable Shares54.18M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Here's Why We're A Bit Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Situation
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.